Patients with vs without rheumatoid arthritis (RA), especially those with RA-associated interstitial lung disease (RA-ILD), have a significantly higher risk of developing lung cancer, according to ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Patients with vs without keloids had a higher prevalence of interstitial lung disease after controlling for patient specific factors.

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell ...

The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

A panel of experts, including Dr Rohit Aggarwal, Principal Investigator of the decentralized Myositis Interstitial Lung ...

The result is a welcome endorsement of patritumab derxutecan's potential after the HER3-directed antibody-drug conjugate (ADC ...

Researchers at the University of Exeter and clinical radiopharmaceutical company Serac Healthcare Ltd are researching a new molecular imaging marker which could help to detect disease progression ...

Researchers at the University of Exeter and clinical radiopharmaceutical company Serac Healthcare Ltd are researching a new molecular imaging marker which could help to detect disease progression ...

Vold, MD, PhD, a senior consultant and leader of inflammatory and fibrotic research area at Oslo University Hospital, shares critical insights into the risk factors and management of interstitial lung ...